These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 24547718)

  • 1. Biologics in nail psoriasis.
    de Berker D
    Br J Dermatol; 2014 Feb; 170(2):236-7. PubMed ID: 24547718
    [No Abstract]   [Full Text] [Related]  

  • 2. Ustekinumab improves nail disease in patients with moderate-to-severe psoriasis: results from PHOENIX 1.
    Rich P; Bourcier M; Sofen H; Fakharzadeh S; Wasfi Y; Wang Y; Kerkmann U; Ghislain PD; Poulin Y;
    Br J Dermatol; 2014 Feb; 170(2):398-407. PubMed ID: 24117389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intramatricial low-dose secukinumab injection for nail psoriasis.
    He F; Long F; Tu J; Yin Z
    Indian J Dermatol Venereol Leprol; 2021; 87(1):116-119. PubMed ID: 32930105
    [No Abstract]   [Full Text] [Related]  

  • 4. Nail Psoriasis: An Updated Review and Expert Opinion on Available Treatments, Including Biologics.
    Bardazzi F; Starace M; Bruni F; Magnano M; Piraccini BM; Alessandrini A
    Acta Derm Venereol; 2019 May; 99(6):516-523. PubMed ID: 30521057
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determination of the Nail Psoriasis Severity Index improvement rate standards for nail psoriasis treatment in a phase IV clinical trial of ustekinumab: the MARCOPOLO study.
    Youn SW; Kim BR; Cho S; Seo SJ; Lee ES; Roh JY; Choi GS; Lee MG;
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):e298-e299. PubMed ID: 27976465
    [No Abstract]   [Full Text] [Related]  

  • 6. Ixekizumab Is Effective in Subjects With Moderate to Severe Plaque Psoriasis With Significant Nail Involvement: Results From UNCOVER 3.
    Dennehy EB; Zhang L; Amato D; Goldblum O; Rich P
    J Drugs Dermatol; 2016 Aug; 15(8):958-61. PubMed ID: 27537996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of nail psoriasis with TNF-α or IL12/23 inhibitors.
    Jemec GB; Ibler KS
    J Drugs Dermatol; 2012 Aug; 11(8):939-42. PubMed ID: 22859238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of ustekinumab in nail psoriasis and improvement in nail-associated quality of life in a population treated with ustekinumab for cutaneous psoriasis: an open prospective unblinded study.
    Rigopoulos D; Gregoriou S; Makris M; Ioannides D
    Dermatology; 2011; 223(4):325-9. PubMed ID: 22134046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Severe recalcitrant nail psoriasis responding dramatically to infliximab: report of two patients.
    Hussain W; Coulson I; Owen C
    Clin Exp Dermatol; 2008 Jul; 33(4):520-2. PubMed ID: 18462438
    [No Abstract]   [Full Text] [Related]  

  • 10. Dermoscopic features of nail psoriasis treated with biologics.
    Hashimoto Y; Uyama M; Takada Y; Yoshida K; Ishiko A
    J Dermatol; 2017 May; 44(5):538-541. PubMed ID: 28150346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nail psoriasis improvement in a patient treated with fumaric acid esters.
    Vlachou C; Berth-Jones J
    J Dermatolog Treat; 2007; 18(3):175-7. PubMed ID: 17538807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients.
    Vitiello M; Tosti A; Abuchar A; Zaiac M; Kerdel FA
    Int J Dermatol; 2013 Mar; 52(3):358-62. PubMed ID: 23330782
    [No Abstract]   [Full Text] [Related]  

  • 13. Scalp and nail psoriasis.
    Lane-Brown MM
    Med J Aust; 1980 Jan; 1(2):82. PubMed ID: 7360098
    [No Abstract]   [Full Text] [Related]  

  • 14. Ustekinumab in nail psoriasis: an open-label, uncontrolled, nonrandomized study.
    Patsatsi A; Kyriakou A; Sotiriadis D
    J Dermatolog Treat; 2013 Apr; 24(2):96-100. PubMed ID: 21797806
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Marked improvement in nail psoriasis during treatment with adalimumab.
    Irla N; Yawalkar N
    Dermatology; 2009; 219(4):353-6. PubMed ID: 19851059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ixekizumab in nail psoriasis.
    Dattola A; Manfreda V; Mazzilli S; Bianchi L; Giunta A
    Dermatol Ther; 2020 May; 33(3):e13352. PubMed ID: 32232895
    [No Abstract]   [Full Text] [Related]  

  • 17. Instability of topical ciclosporin emulsion for nail psoriasis.
    Prins AM; Vos K; Franssen EJ
    Dermatology; 2007; 215(4):362-3. PubMed ID: 17911999
    [No Abstract]   [Full Text] [Related]  

  • 18. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT).
    Paul C; Puig L; Kragballe K; Luger T; Lambert J; Chimenti S; Girolomoni G; Nicolas JF; Rizova E; Lavie F; Mistry S; Bergmans P; Barker J; Reich K;
    Br J Dermatol; 2014 Feb; 170(2):425-34. PubMed ID: 24116959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up.
    Papp KA; Griffiths CE; Gordon K; Lebwohl M; Szapary PO; Wasfi Y; Chan D; Hsu MC; Ho V; Ghislain PD; Strober B; Reich K; ; ;
    Br J Dermatol; 2013 Apr; 168(4):844-54. PubMed ID: 23301632
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treat to Target in Psoriasis: A Real-World Experience With Biologics and Adjunctive Topical Therapy.
    Bagel J
    J Drugs Dermatol; 2018 Aug; 17(8):918. PubMed ID: 30124735
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.